Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

Salim S. Virani; Julia M. Akeroyd; Sidney C. Smith; Mouaz Al-Mallah; Thomas M. Maddox; Pamela B. Morris; Laura A. Petersen; Christie M. Ballantyne; Scott M. Grundy; Neil J. Stone

doi:10.1016/j.jacc.2019.05.051

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

Salim S. Virani, Julia M. Akeroyd, Sidney C. Smith, Mouaz Al-Mallah, Thomas M. Maddox, Pamela B. Morris, Laura A. Petersen, Christie M. Ballantyne, Scott M. Grundy, Neil J. Stone

Research output: Contribution to journal › Letter › peer-review

20 Scopus citations

Original language	English (US)
Pages (from-to)	712-714
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	74
Issue number	5
DOIs	https://doi.org/10.1016/j.jacc.2019.05.051
State	Published - Aug 6 2019

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2019.05.051

Cite this

Virani, S. S., Akeroyd, J. M., Smith, S. C., Al-Mallah, M., Maddox, T. M., Morris, P. B., Petersen, L. A., Ballantyne, C. M., Grundy, S. M., & Stone, N. J. (2019). Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology, 74(5), 712-714. https://doi.org/10.1016/j.jacc.2019.05.051

@article{165a049fd32341789dc6a49c755639aa,

title = "Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines",

author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Smith, {Sidney C.} and Mouaz Al-Mallah and Maddox, {Thomas M.} and Morris, {Pamela B.} and Petersen, {Laura A.} and Ballantyne, {Christie M.} and Grundy, {Scott M.} and Stone, {Neil J.}",

note = "Funding Information: Please note: This work was supported by a Department of Veterans Affairs Health Services Research & Development (HSR&D) Service Investigator Initiated Grant (IIR 16-072), American Heart Association Beginning Grant-in-Aid (14BGIA20460366), and the Houston VA HSR&D Center for Innovations grant (grant CIN13-413). Dr. Maddox is supported by the National Institutions of Health/NCATS (1U24TR002306-01: A National Center for Digital Health Informatics Innovation). The opinions expressed reflect those of the authors and are not necessarily those of the Department of Veterans Affairs, the U.S. Government, or Baylor College of Medicine. Dr. Virani has received honorarium from the American College of Cardiology as the Associate Editor for Innovations. Dr. Maddox has been consultant for Creative Educational Concepts; and has received honoraria from Brown University, Washington State Clinical Outcomes Assessment Program (COAP), Virginia Mason, University of Utah, New York Presbyterian, Westchester Medical Center, Sentara Heart Hospital, and the Henry Ford Health System. Dr. Morris has been a member of the Advisory Board and a consultant for Amgen, Sanofi, and Regeneron. Dr. Ballantyne has served as a consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2019",

month = aug,

day = "6",

doi = "10.1016/j.jacc.2019.05.051",

language = "English (US)",

volume = "74",

pages = "712--714",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Smith, Sidney C.

AU - Al-Mallah, Mouaz

AU - Maddox, Thomas M.

AU - Morris, Pamela B.

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

AU - Grundy, Scott M.

AU - Stone, Neil J.

N1 - Funding Information: Please note: This work was supported by a Department of Veterans Affairs Health Services Research & Development (HSR&D) Service Investigator Initiated Grant (IIR 16-072), American Heart Association Beginning Grant-in-Aid (14BGIA20460366), and the Houston VA HSR&D Center for Innovations grant (grant CIN13-413). Dr. Maddox is supported by the National Institutions of Health/NCATS (1U24TR002306-01: A National Center for Digital Health Informatics Innovation). The opinions expressed reflect those of the authors and are not necessarily those of the Department of Veterans Affairs, the U.S. Government, or Baylor College of Medicine. Dr. Virani has received honorarium from the American College of Cardiology as the Associate Editor for Innovations. Dr. Maddox has been consultant for Creative Educational Concepts; and has received honoraria from Brown University, Washington State Clinical Outcomes Assessment Program (COAP), Virginia Mason, University of Utah, New York Presbyterian, Westchester Medical Center, Sentara Heart Hospital, and the Henry Ford Health System. Dr. Morris has been a member of the Advisory Board and a consultant for Amgen, Sanofi, and Regeneron. Dr. Ballantyne has served as a consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2019/8/6

Y1 - 2019/8/6

UR - http://www.scopus.com/inward/record.url?scp=85069568245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069568245&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.05.051

DO - 10.1016/j.jacc.2019.05.051

M3 - Letter

C2 - 31370962

AN - SCOPUS:85069568245

SN - 0735-1097

VL - 74

SP - 712

EP - 714

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 5

ER -

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this